Vyome Holdings (HIND) AI Stock Analysis

• Market Cap: $16.00M
• Dividend Yield: N/A
• Average Volume (3M): 91.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: -48.74%
• EPS Growth: 89.18%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.12
• Shares Outstanding: 7,018,528
• 10 Day Avg. Volume: 49,999
• 30 Day Avg. Volume: 91,100
• PEG Ratio: <0.01
• Price to Book (P/B): 3.04
• Price to Sales (P/S): 23.26
• P/FCF Ratio: -1.98
• Enterprise Value/Market Cap: 0.49
• Enterprise Value/Revenue: 3.26
• Enterprise Value/Gross Profit: 36.19
• Enterprise Value/Ebitda: -2.90
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.82
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $2.00 ▼(-63.10% Downside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

Overall score is dragged down primarily by weak financial performance (persistent losses, negative free cash flow, and a sharp TTM revenue decline) and bearish technicals (below major DMAs with negative MACD). Valuation support is limited due to a loss-making profile and no dividend, while recent corporate updates are a modest positive offset.

Positive Factors

Clinical progress (VT-1953 Phase 2)

Positive Phase 2 investigator‑sponsored data for VT‑1953 demonstrates meaningful symptom relief, favorable tolerability, and QoL gains in an underserved oncology niche. This de‑risks the lead asset, strengthens partnering and licensing prospects, and supports a durable clinical development pathway toward Phase 3.

Clear market opportunity for VT‑1953

An independent market assessment quantifies a sizable, growing addressable market with limited late‑stage competition, positioning VT‑1953 as potentially first‑in‑class. Structural unmet need and modeled commercial value increase long‑term partner interest and justify continued clinical investment.

Strategic optionality via Livechain Humanyze deal

The Humanyze acquisition repositions a Vyome subsidiary into AI HR analytics, creating a separate growth engine and potential uplisting path. Structuring the deal within Livechain limits direct capital exposure for Vyome while adding diversification and potential long‑term upside outside core biotech operations.

Negative Factors

Persistent cash burn

Consistent negative operating and free cash flow across all reported periods indicates the company cannot self‑fund development or commercialization. Ongoing burn constrains strategic optionality, elevates financing frequency, and creates dilution risk that materially affects long‑term execution and asset progression.

Deeply negative profitability & collapsed revenue

Sustained negative margins and a dramatic TTM revenue collapse severely weaken operating leverage and cash runway. This undermines the firm's ability to scale or negotiate favorable partner deals, increases reliance on external funding, and raises execution risk for clinical and commercial plans over the coming months.

Governance and dilution risk from related‑party deals

The complex, related‑party Humanyze transaction introduces governance complexity and meaningful dilution at the subsidiary level. Director recusals and large equity grants to a counterparty create execution and oversight risk, and may complicate future capital raises or partner negotiations for both Livechain and Vyome shareholders.

Vyome Holdings Business Overview & Revenue Model

Company Description

Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Princeton, New Jersey.

Vyome Holdings Financial Statement Overview

Summary

Financial profile is weak: sustained operating losses (deeply negative EBIT/EBITDA and net margins) and negative operating/free cash flow across all periods indicate ongoing cash burn and funding dependence. Low leverage in TTM is a partial offset, but equity volatility (including turning negative in 2024) and the sharp TTM revenue collapse materially increase financing and execution risk.

Income Statement

Vyome Holdings shows consistently negative profitability across the period, with deeply negative EBIT/EBITDA and net margins, indicating a business still in heavy investment mode. While gross margin remains relatively stable and healthy (~55%–64%), revenue has contracted in most years and collapsed in TTM (Trailing-Twelve-Months) (down ~92% vs. the prior period), which materially worsens operating leverage and increases reliance on external funding.

Balance Sheet

Leverage is currently low in TTM (Trailing-Twelve-Months) (debt-to-equity ~0.02), which is a key stabilizer for a loss-making biotech. However, equity has been volatile and even turned negative in 2024, highlighting balance-sheet fragility and potential dilution/financing risk. Returns on equity are generally weak/negative (and distorted when equity is negative), consistent with persistent losses.

Cash Flow

Cash generation remains a major weakness: operating cash flow and free cash flow are negative in every period shown, including TTM (Trailing-Twelve-Months), signaling ongoing cash burn. The cash burn improved versus 2023 levels, and free cash flow trends look better than the prior year in TTM (Trailing-Twelve-Months), but the business still lacks self-funding capacity and will likely require continued capital raises.

Breakdown	Dec 2025	Mar 2025	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	319.71K	8.01M	8.68M	11.24M	13.60M
Gross Profit	218.77K	5.06M	5.55M	6.80M	8.35M
EBITDA	-2.74M	-6.65M	-11.18M	-44.33M	-60.62M
Net Income	-10.26M	-7.13M	-11.39M	-46.21M	-63.15M
Balance Sheet
Total Assets	6.50M	4.79M	10.73M	11.27M	52.53M
Cash, Cash Equivalents and Short-Term Investments	4.98M	693.00K	4.56M	3.96M	22.77M
Total Debt	31.26K	967.00K	262.00K	171.00K	279.00K
Total Liabilities	2.74M	5.05M	4.06M	7.60M	8.20M
Stockholders Equity	2.44M	-253.00K	6.66M	3.66M	44.33M
Cash Flow
Free Cash Flow	-3.75M	-4.43M	-17.00M	-22.03M	-15.73M
Operating Cash Flow	-3.75M	-4.43M	-16.96M	-21.90M	-15.38M
Investing Cash Flow	0.00	0.00	-10.00K	-92.00K	1.85M
Financing Cash Flow	8.65M	677.00K	17.57M	3.13M	33.30M

Vyome Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIND, the sentiment is Negative. The current price of 5.42 is above the 20-day moving average (MA) of 2.75, above the 50-day MA of 2.74, and below the 200-day MA of 6.35, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 38.94 is Neutral, neither overbought nor oversold. The STOCH value of 23.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIND.

Vyome Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOVE	47 Neutral	$16.00M	-27.76	-647.90%	―	-44.57%	55.97%
HIND	44 Neutral	$16.00M	-0.72	-364.96%	―	-48.74%	89.18%
SINT	42 Neutral	$9.59M	-0.63	-204.04%	―	-60.89%	94.49%
HSDT	41 Neutral	$84.25M	-0.03	1028.60%	―	87.45%	72.30%
VERO	41 Neutral	$625.39K	-0.05	-2268.26%	―	-12.39%	44.61%
HSCS	40 Underperform	$8.12M	-1.29	-220.42%	―	-41.03%	35.71%

Vyome Holdings Corporate Events

Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics

On February 20, 2026, Vyome’s subsidiary Livechain, Inc. and its unit LICH AI Inc. entered into a Notes Purchase and Exchange Agreement with Remus Capital to acquire $5.77 million in senior secured convertible notes of Sociometric Solutions, Inc., d/b/a Humanyze, in an all-stock deal. As consideration, Livechain agreed to issue Remus roughly 211.2 million common shares, equal to 25% of Livechain’s fully diluted equity immediately before closing, and to reserve additional stock for employee compensation in connection with the transaction.

Under the structure, Livechain has triggered a default and asset transfer so that LICH AI Inc. will assume substantially all of Humanyze’s assets, including intellectual property and trade secrets, and take direct control of its operations to build an AI-enabled HR analytics business. The related-party transaction, which was approved by Vyome’s audit committee and board with conflicted Remus-affiliated directors recusing themselves, is intended to reposition Livechain in the high-growth AI HR sector and create a potential path to a future uplisting, while limiting Vyome’s capital and operational exposure and offering upside for both Livechain and Vyome shareholders.

On February 24, 2026, Vyome announced the agreement’s execution, highlighting Humanyze’s roots in the MIT Media Lab and its focus on science-based, AI-driven workforce analytics for large enterprises. The deal structure includes obligations for Remus to keep Humanyze active to manage select legacy liabilities and creates a framework for Livechain to raise its own capital independently as it integrates Humanyze and develops a scalable AI platform around human capital management.

The most recent analyst rating on (HIND) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.

Vyome Reports Positive Phase 2 Data for VT-1953 Gel

Vyome Holdings reported Phase 2 investigator-sponsored trial results for VT-1953, a 2% topical gel for malignant fungating wounds, demonstrating statistically significant reductions in malodor by Day 14 versus both baseline and vehicle, with 80% of treated patients achieving a greater than two-point malodor improvement. The study, which also showed meaningful gains in patient-reported quality of life and pain relief with a favorable tolerability profile, underpins further clinical development of VT-1953 and reinforces Vyome’s strategic positioning in an underserved niche of supportive cancer care.

The most recent analyst rating on (HIND) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.

Vyome Holdings Highlights VT-1953 Market Potential Analysis

On January 27, 2026, Vyome Holdings released new data from an independent U.S. market assessment, commercial forecast and valuation analysis for VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. The study by Destum Partners highlights significant unmet need in this end-of-life oncology complication, identifies an absence of approved or late-stage competing therapies, and positions VT-1953 as a potential first-in-class topical treatment designed to address multiple core symptoms including malodor and pain. Destum’s base-case rNPV analysis values VT-1953 at $455 million in the United States as of Phase 2 completion, with modeled asset value rising to more than $1 billion in 2028 following anticipated Phase 3 completion, and implies a total U.S. addressable pharmacologic market for malignant fungating wound symptom treatment of about $2.2 billion in 2026, growing to $2.8 billion by 2040, underscoring the asset’s potential clinical and commercial importance and the strategic relevance of securing a partner with strong oncology supportive or wound-care capabilities.

The most recent analyst rating on (HIND) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.

Vyome’s LiveChain Signs LOI for Humanyze Note Acquisition

On December 17, 2025, Vyome Holdings, Inc., through its indirect subsidiary LiveChain, Inc. (LICH), entered into a binding letter of intent with Remus Capital Series B II, L.P. to acquire a senior secured convertible note issued by Sociometric Solutions, Inc., d/b/a Humanyze, in exchange for issuing Remus a 25% fully diluted equity stake in LICH immediately prior to closing, with an additional 10% of LICH’s equity reserved for key and future employees, leaving current shareholders with an expected 65% post-closing stake. The transaction, treated as a related party deal and approved by both the company’s Audit Committee and Board after the recusal of Remus-affiliated directors, will be executed through a newly formed LICH subsidiary under a Note Purchase and Exchange Agreement, includes a $20,000 good-faith deposit to Humanyze, grants Remus the right to appoint one LICH director, and is structured to be completed within roughly 75 days of the LOI execution, potentially reshaping LICH’s capital structure and governance while ensuring Humanyze remains active to service select obligations.

The most recent analyst rating on (HIND) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.